About the Company

Genticel (Euronext: GTCL.PA) is a clinical-stage biotechnology company developing a bivalent therapeutic vaccine for women infected with high-risk strains of the human papillomavirus (HPV), which are responsible for the majority of cervical cancer cases. The Company’s lead development candidate, ProCervix, promotes HPV clearance in women who have already been infected with the virus before it can induce cancer. ProCervix is currently under evaluation in a Phase II trial in Europe, with preliminary efficacy results expected in the first half of 2016. Genticel is also developing a multivalent HPV vaccine against 6 HPV genotypes using its proprietary Vaxiclase technology platform and is pursuing licensing agreements covering the use of Vaxiclase multiple vaccine indications.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research